{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:02:18Z","timestamp":1789599738011,"version":"build-2803163510"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"29","funder":[{"DOI":"10.13039\/501100004564","name":"Ministry of Education, Science and Technological Development-Republic of Serbia","doi-asserted-by":"publisher","award":["175023"],"award-info":[{"award-number":["175023"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,10,26]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Clinical evaluation of the Endothelial Function (EF) is becoming an\nessential step in the quality assessment of cardiovascular risk prevention and rational pharmacotherapy\nof cardiovascular disorders. The existing pieces of evidence suggested that Calcium\nChannel Blockers (CCB) can induce positive effects on impaired EF.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To evaluate the effects of CCB on EF, we performed a meta-analysis of available\ndata from randomized and placebo-controlled or other treatment-controlled clinical studies\nencompassing effects of CCB on EF, as measured by Flow-Mediated Dilation (FMD) of the\nbrachial artery.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The relevant clinical studies were searched by systematic exploration of the appropriate\ndatabases until November 30, 2017. A random-effect model was conducted. The primary\noutcome was the percentage change in FMD between the baseline and the final levels in\nresponse to investigated drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Fifteen randomized clinical studies with 33 arms were identified. CCB improved\nFMD more pronounced than thiazide diuretics - TD (3 studies, 157 participants,\nWMD=2.08%, 95% CI=0.35-3.80%; P=0.02). Oppositely, ACE Inhibitors (ACEI) and Angiotensin\nReceptor Blockers (ARB) notably improved FMD if compared to CCB (CCB vs.\nACEI: 5 studies, 533 participants, WMD = \u20101.62%, 95% CI = \u20102.74% to \u20100.50%; P=0.005;\nand CCB vs. ARB: 9 studies, 669 participants, WMD = \u20101.52%, 95% CI = \u20102.22% to\n\u20100.81%; P=0.0001). CCB effects on EF were similar to those evoked by beta blockers or placebo.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>CCB improved EF to a more prominent extent only if paralleled to TD, while\ninversely; ACEI and ARB were more effective in augmenting FMD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867325666180713144806","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T03:29:09Z","timestamp":1572060549000},"page":"5579-5595","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Calcium Channel Blockers in Restoration of Endothelial Function: Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.2174","volume":"26","author":[{"given":"Miroslav","family":"Radenkovi\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Stojanovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Prostran","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002487","volume":"95","author":"Wang Y.C.","year":"2016","unstructured":"Wang Y.C.; Hsieh T.C.; Chou C.L.; Wu J.L.; Fang T.C.; Calcium channel blockers. Medicine (Baltimore) 2016,95(2)","journal-title":"Medicine (Baltimore)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12013-014-0498-z","volume":"72","author":"Gao B.","year":"2015","unstructured":"Gao B.; Zhang Z.; Qian J.; Cao C.; Hua X.; Chu M.; He X.; Zeng H.; The Use of calcium channel blockers in the treatment of coronary spasm and atrioventricular block. Cell Biochem Biophys 2015,72(2),527-531","journal-title":"Cell Biochem Biophys"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00044-012-0211-y","volume":"22","author":"Nalwaya R.","year":"2013","unstructured":"Nalwaya R.; Sahai A.; Chander S.; Sharma M.; Malik R.; Sarsodia G.; Synthesis, characterization, and pharmacological evaluation of benzothiopyran derivatives as a novel class of calcium channel blockers. Med Chem Res 2013,22(5),2188-2195","journal-title":"Med Chem Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1074248414555403","volume":"20","author":"Tocci G.","year":"2015","unstructured":"Tocci G.; Battistoni A.; Passerini J.; Musumeci M.B.; Francia P.; Ferrucci A.; Volpe M.; Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther 2015,20(2),121-130","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/1099800413494760","volume":"16","author":"Shields D.L.","year":"2014","unstructured":"Shields D.L.; Calcium channel blockers as initial therapeutic agents in hypertension: relationship to incident heart failure. Biol Res Nurs 2014,16(3),266-277","journal-title":"Biol Res Nurs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11906-012-0269-4","volume":"14","author":"Preston Mason R.","year":"2012","unstructured":"Preston Mason R.; Pleiotropic effects of calcium channel blockers. Curr Hypertens Rep 2012,14(4),293-303","journal-title":"Curr Hypertens Rep"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1475-2840-10-79","volume":"10","author":"Fukao K.","year":"2011","unstructured":"Fukao K.; Shimada K.; Hiki M.; Kiyanagi T.; Hirose K.; Kume A.; Ohsaka H.; Matsumori R.; Kurata T.; Miyazaki T.; Daida H.; Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT). Cardiovasc Diabetol 2011,10,79","journal-title":"Cardiovasc Diabetol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1152\/physrev.00018.2002","volume":"83","author":"Perez-Reyes E.","year":"2003","unstructured":"Perez-Reyes E.; Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003,83(1),117-161","journal-title":"Physiol Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/01.HYP.37.1.34","volume":"37","author":"Brovkovych V.","year":"2001","unstructured":"Brovkovych V.; Kalinowski L.; Muller-Peddinghaus R.; Malinski T.; Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension 2001,37(1),34-39","journal-title":"Hypertension"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00005344-199908000-00001","volume":"34","author":"Kobayashi N.","year":"1999","unstructured":"Kobayashi N.; Yanaka H.; Tojo A.; Kobayashi K.; Matsuoka H.; Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol 1999,34(2),173-181","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4330\/wjc.v7.i11.719","volume":"7","author":"Su J.B.","year":"2015","unstructured":"Su J.B.; Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol 2015,7(11),719-741","journal-title":"World J Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1042\/CS20120311","volume":"125","author":"Yasu T.","year":"2013","unstructured":"Yasu T.; Kobayashi M.; Mutoh A.; Yamakawa K.; Momomura S.; Ueda S.; Dihydropyridine calcium channel blockers inhibit non-esterified-fatty-acid-induced endothelial and rheological dysfunction. Clin Sci (Lond) 2013,125(5),247-255","journal-title":"Clin Sci (Lond)"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039162","volume":"7","author":"Yamamoto E.","year":"2012","unstructured":"Yamamoto E.; Kataoka K.; Dong Y.F.; Koibuchi N.; Toyama K.; Sueta D.; Katayama T.; Yasuda O.; Ogawa H.; Kim-Mitsuyama S.; Calcium channel blockers, more than diuretics, enhance vascular protective effects of angiotensin receptor blockers in salt-loaded hypertensive rats. PLoS One 2012,7(6)","journal-title":"PLoS One"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1254\/jphs.13178FP","volume":"124","author":"Okamura T.","year":"2014","unstructured":"Okamura T.; Tawa M.; Geddawy A.; Shimosato T.; Iwasaki H.; Shintaku H.; Yoshida Y.; Masada M.; Shinozaki K.; Imamura T.; Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. J Pharmacol Sci 2014,124(1),76-85","journal-title":"J Pharmacol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1253\/circj.CJ-09-0743","volume":"74","author":"Kubota N.","year":"2010","unstructured":"Kubota N.; Miyauchi K.; Kasai T.; Iesaki T.; Kajimoto K.; Sumiyoshi K.; Dohi T.; Daida H.; Synergistic effects of calcium-channel and angiotensin-receptor blockers on endothelial function and inflammatory responses in a porcine drug-eluting stent model. Circ J 2010,74(8),1704-1710","journal-title":"Circ J"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/01.HYP.37.3.943","volume":"37","author":"Taddei S.","year":"2001","unstructured":"Taddei S.; Virdis A.; Ghiadoni L.; Magagna A.; Favilla S.; Pompella A.; Salvetti A.; Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001,37(3),943-948","journal-title":"Hypertension"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/01.CIR.0000046488.52939.BF","volume":"107","year":"2003","unstructured":"Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation ENCORE Investigators2003,107(3),422-428","journal-title":"Circulation"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1093\/eurheartj\/ehp151","volume":"30","author":"L\u00fcscher T.F.","year":"2009","unstructured":"L\u00fcscher T.F.; Pieper M.; Tendera M.; Vrolix M.; Rutsch W.; van den Branden F.; Gil R.; Bischoff K.O.; Haude M.; Fischer D.; Meinertz T.; M\u00fcnzel T.; A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009,30(13),1590-1597","journal-title":"Eur Heart J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/08037051.2016.1184495","volume":"25","author":"De Ciuceis C.","year":"2016","unstructured":"De Ciuceis C.; Rossini C.; Tincani A.; Air\u00f2 P.; Scarsi M.; Agabiti-Rosei C.; Ruggeri G.; Caimi L.; Ricotta D.; Agabiti-Rosei E.; Rizzoni D.; Effect of antihypertensive treatment with lercanidipine on endothelial progenitor cells and inflammation in patients with mild to moderate essential hypertension. Blood Press 2016,25(6),337-343","journal-title":"Blood Press"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijcard.2009.05.019","volume":"139","author":"Clunn G.F.","year":"2010","unstructured":"Clunn G.F.; Sever P.S.; Hughes A.D.; Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers. Int J Cardiol 2010,139(1),2-6","journal-title":"Int J Cardiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/ajh.2008.258","volume":"21","author":"Mizuno Y.","year":"2008","unstructured":"Mizuno Y.; Jacob R.F.; Mason R.P.; Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens 2008,21(10),1076-1085","journal-title":"Am J Hypertens"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1007\/s11095-007-9491-1","volume":"25","author":"Mason R.P.","year":"2008","unstructured":"Mason R.P.; Kubant R.; Heeba G.; Jacob R.F.; Day C.A.; Medlin Y.S.; Funovics P.; Malinski T.; Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res 2008,25(8),1798-1806","journal-title":"Pharm Res"},{"key":"ref=23","first-page":"3821","volume":"28","author":"Xin-Ke Z.","year":"2017","unstructured":"Xin-Ke Z.; Ming-Xia F.; Ai-ling Q.; Kai L.; Xu Z.; Ying-dong L.; Amlodipine\/atorvastatin has an effect on vascular function and normal lipid levels. Biomed Res (Aligarh) 2017,28(9),3821-3825","journal-title":"Biomed Res (Aligarh)"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/252158","volume":"2013","author":"Radenkovi\u0107 M.","year":"2013","unstructured":"Radenkovi\u0107 M.; Stojanovi\u0107 M.; Potpara T.; Prostran M.; Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art. BioMed Res Int 2013,2013","journal-title":"BioMed Res Int"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"H2","DOI":"10.1152\/ajpheart.00471.2010","volume":"300","author":"Thijssen D.H.","year":"2001","unstructured":"Thijssen D.H.; Black M.A.; Pyke K.E.; Padilla J.; Atkinson G.; Harris R.A.; Parker B.; Widlansky M.E.; Tschakovsky M.E.; Green D.J.; Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2001,300(1),H2-H12","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/1755-5922.12122","volume":"33","author":"Stojanovi\u0107 M.","year":"2015","unstructured":"Stojanovi\u0107 M.; Radenkovi\u0107 M.; Vitamin D versus placebo in improvement of endothelial dysfunction: a meta-analysis of randomized clinical trials. Cardiovasc Ther 2015,33(3),145-154","journal-title":"Cardiovasc Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00228-015-1999-4","volume":"72","author":"Stojanovi\u0107 M.","year":"2016","unstructured":"Stojanovi\u0107 M.; Prostran M.; Radenkovi\u0107 M.; Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 2016,72(4),385-398","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"Liberati A.","year":"2009","unstructured":"Liberati A.; Altman D.G.; Tetzlaff J.; Mulrow C.; G\u00f8tzsche P.C.; Ioannidis J.P.; Clarke M.; Devereaux P.J.; Kleijnen J.; Moher D.; The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009,6(7)","journal-title":"PLoS Med"},{"key":"ref=29","author":"Higgins J.","year":"2011","unstructured":"Higgins J.; Green S.;  Cochrane Handbook for Systematic Reviews of Interventions Version 530 2011","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 530"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"Jadad A.R.","year":"1996","unstructured":"Jadad A.R.; Moore R.A.; Carroll D.; Jenkinson C.; Reynolds D.J.M.; Gavaghan D.J.; McQuay H.J.; Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996,17(1),1-12","journal-title":"Control Clin Trials"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090217","volume":"9","author":"Li S.","year":"2014","unstructured":"Li S.; Wu Y.; Yu G.; Xia Q.; Xu Y.; Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials. PLoS One 2014,9(3)","journal-title":"PLoS One"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"Higgins J.P.","year":"2003","unstructured":"Higgins J.P.; Thompson S.G.; Deeks J.J.; Altman D.G.; Measuring inconsistency in meta-analyses. BMJ 2003,327(7414),557-560","journal-title":"BMJ"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0735-1097(99)00537-9","volume":"35","author":"Anderson T.J.","year":"2000","unstructured":"Anderson T.J.; Elstein E.; Haber H.; Charbonneau F.; Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000,35(1),60-66","journal-title":"J Am Coll Cardiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ijcard.2004.03.046","volume":"101","author":"Bae J.H.","year":"2005","unstructured":"Bae J.H.; Bassenge E.; Lim D.M.; Synn Y.C.; Kim K.Y.; Schwemmer M.; Effects of lacidipine on vascular responses in patients with coronary artery disease. Int J Cardiol 2005,101(3),377-383","journal-title":"Int J Cardiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/FJC.0b013e31811dfbe7","volume":"50","author":"Benndorf R.A.","year":"2007","unstructured":"Benndorf R.A.; Appel D.; Maas R.; Schwedhelm E.; Wenzel U.O.; B\u00f6ger R.H.; Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007,50(4),367-371","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0021-9150(00)00455-X","volume":"154","author":"Clarkson P.","year":"2001","unstructured":"Clarkson P.; Mullen M.J.; Donald A.E.; Powe A.J.; Thomson H.; Thorne S.A.; Bull T.; Deanfield J.E.; The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. Atherosclerosis 2001,154(1),171-177","journal-title":"Atherosclerosis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00044011-200222070-00005","volume":"22","author":"Fang L.","year":"2002","unstructured":"Fang L.; Zheng F.; Qingyin T.; Ming Z.; Yanyan H.; Effect of ramipril on endothelial dysfunction in patients with essential hyperten-sion. Clin Drug Investig 2002,22(7),449-453","journal-title":"Clin Drug Investig"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/clpt.2011.227","volume":"91","author":"Fujimura N.","year":"2012","unstructured":"Fujimura N.; Noma K.; Hata T.; Soga J.; Hidaka T.; Idei N.; Fujii Y.; Mikami S.; Maruhashi T.; Iwamoto Y.; Kihara Y.; Chayama K.; Kato H.; Liao J.K.; Higashi Y.; Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther ROCK Study Group2012,91(2),289-297","journal-title":"Clin Pharmacol Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","volume":"41","author":"Ghiadoni L.","year":"2003","unstructured":"Ghiadoni L.; Magagna A.; Versari D.; Kardasz I.; Huang Y.; Taddei S.; Salvetti A.; Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003,41(6),1281-1286","journal-title":"Hypertension"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2008.11.017","volume":"140","author":"Koh K.K.","year":"2010","unstructured":"Koh K.K.; Quon M.J.; Han S.H.; Lee Y.; Kim S.J.; Koh Y.; Shin E.K.; Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010,140(1),73-81","journal-title":"Int J Cardiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1291\/hypres.29.567","volume":"29","author":"Morimoto S.","year":"2006","unstructured":"Morimoto S.; Yano Y.; Maki K.; Sawada K.; Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006,29(8),567-572","journal-title":"Hypertens Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/01.HYP.33.1.575","volume":"33","author":"Muiesan M.L.","year":"1999","unstructured":"Muiesan M.L.; Salvetti M.; Monteduro C.; Rizzoni D.; Zulli R.; Corbellini C.; Brun C.; Agabiti-Rosei E.; Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999,33(1 Pt 2),575-580","journal-title":"Hypertension"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/08037051.2011.561072","volume":"20","author":"Muiesan M.L.","year":"2011","unstructured":"Muiesan M.L.; Salvetti M.; Belotti E.; Paini A.; Rosei C.A.; Aggiusti C.; Scotti A.; de Ciuceis C.; Rizzoni D.; Rosei E.A.; Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients. Blood Press 2011,20(4),244-251","journal-title":"Blood Press"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/hr.2011.11","volume":"34","author":"Takiguchi S.","year":"2011","unstructured":"Takiguchi S.; Ayaori M.; Uto-Kondo H.; Iizuka M.; Sasaki M.; Komatsu T.; Takase B.; Adachi T.; Ohsuzu F.; Ikewaki K.; Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertens Res 2011,34(6),686-692","journal-title":"Hypertens Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/S0002-9149(01)01567-3","volume":"87","author":"Uehata A.","year":"2001","unstructured":"Uehata A.; Takase B.; Nishioka T.; Kitamura K.; Akima T.; Kurita A.; Isojima K.; Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. Am J Cardiol 2001,87(12),1414-1416","journal-title":"Am J Cardiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1755-5949.2012.00304.x","volume":"18","author":"Wei D.","year":"2012","unstructured":"Wei D.; He W.Y.; Lv Q.Z.; Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients. CNS Neurosci Ther 2012,18(5),400-405","journal-title":"CNS Neurosci Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.2215\/CJN.01110210","volume":"5","author":"Yilmaz M.I.","year":"2010","unstructured":"Yilmaz M.I.; Carrero J.J.; Mart\u00edn-Ventura J.L.; Sonmez A.; Saglam M.; Celik T.; Yaman H.; Yenicesu M.; Eyileten T.; Moreno J.A.; Egido J.; Blanco-Colio L.M.; Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010,5(7),1174-1181","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3797\/scipharm.1407-16","volume":"82","author":"Radenkovi\u0107 M.","year":"2014","unstructured":"Radenkovi\u0107 M.; Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications. Sci Pharm 2014,82(4),709-721","journal-title":"Sci Pharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/apha.12646","volume":"219","author":"Vanhoutte P.M.","year":"2017","unstructured":"Vanhoutte P.M.; Shimokawa H.; Feletou M.; Tang E.H.C.; Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf) 2017,219(1),22-96","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/08037050410033312","volume":"13","author":"Chung N.A.","year":"2004","unstructured":"Chung N.A.; Beevers D.G.; Lip G.; Effects of losartan versus hydrochlorothiazide on indices of endothelial damage\/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press 2004,13(3),183-189","journal-title":"Blood Press"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ajh\/hpu119","volume":"28","author":"Raptis A.E.","year":"2015","unstructured":"Raptis A.E.; Markakis K.P.; Mazioti M.C.; Ikonomidis I.; Maratou E.P.; Vlahakos D.V.; Kotsifaki E.E.; Voumvourakis A.N.; Tsirogianni A.G.; Lambadiari V.A.; Lekakis J.P.; Raptis S.A.; Dimitriadis G.D.; Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. Am J Hypertens 2015,28(1),22-29","journal-title":"Am J Hypertens"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1753944716678538","volume":"11","author":"Rubio-Guerra A.F.","year":"2017","unstructured":"Rubio-Guerra A.F.; Garro-Almendaro A.K.; Elizalde-Barrera C.I.; Suarez-Cuenca J.A.; Duran-Salgado M.B.; Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther Adv Cardiovasc Dis 2017,11(2),57-62","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2011.02.044","volume":"216","author":"Shahin Y.","year":"2011","unstructured":"Shahin Y.; Khan J.A.; Samuel N.; Chetter I.; Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011,216(1),7-16","journal-title":"Atherosclerosis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ajh\/hpt158","volume":"27","author":"Fukutomi M.","year":"2014","unstructured":"Fukutomi M.; Hoshide S.; Mizuno H.; Kario K.; Differential effects of aliskiren\/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients. Am J Hypertens 2014,27(1),14-20","journal-title":"Am J Hypertens"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/08037051.2014.972816","volume":"24","author":"Cel\u0131k T.","year":"2015","unstructured":"Cel\u0131k T.; Balta S.; Karaman M.; Ahmet Ay S.; Dem\u0131rkol S.; Ozturk C.; D\u0131nc M.; Unal H.U.; Y\u0131lmaz M.I.; K\u0131l\u0131c S.; Kurt G.; Tas A.; Iy\u0131soy A.; Quart\u0131-Trevano F.; F\u0131c\u0131 F.; Grass\u0131 G.; Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press 2015,24(1),55-60","journal-title":"Blood Press"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"708","DOI":"10.5603\/CJ.a2015.0042","volume":"22","author":"Peller M.","year":"2015","unstructured":"Peller M.; Oziera\u0144ski K.; Balsam P.; Grabowski M.; Filipiak K.J.; Opolski G.; Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials. Cardiol J 2015,22(6),708-716","journal-title":"Cardiol J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12872-016-0237-z","volume":"16","author":"Derosa G.","year":"2016","unstructured":"Derosa G.; Mugellini A.; Pesce R.M.; D\u2019Angelo A.; Maffioli P.; Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC Cardiovasc Disord 2016,16(1),66","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/10641963.2017.1306537","volume":"39","author":"Zhou T.","year":"2017","unstructured":"Zhou T.; Huang X.; Cai X.; Xie L.; Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives. Clin Exp Hypertens 2017,39(7),612-618","journal-title":"Clin Exp Hypertens"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/163760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T05:45:04Z","timestamp":1574919904000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/163760\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,26]]},"references-count":58,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,10,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180713144806","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}